ESC 2023 Highlights Podcast

In this episode, Medicom’s correspondent covers 6 presentations [13.05] from the European Society of Cardiology Congress (ESC 2023), held in Amsterdam, the Netherlands from 25-28 August 2023.
The topics discussed are:

1. STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity
   In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, treatment with semaglutide resulted in greater weight loss and improved HF-related symptoms compared with placebo. Together with the favourable safety profile, semaglutide presents itself as a practice-changing therapy in this patient population.
2. Inorganic nitrate strongly reduces CIN in high-risk patients undergoing angiography
   Dietary inorganic nitrate significantly reduced contrast-induced nephropathy (CIN) in patients at risk for renal injury undergoing coronary angiography for acute coronary syndrome. Moreover, long-term renal and cardiovascular outcomes in the NITRATE-CIN trial were in favour of patients treated with inorganic nitrate compared with placebo.
3. Acoramidis improves survival and functional status in ATTR-CM
   Acoramidis demonstrated clinical and functional benefits over placebo in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM trial. The agent was well tolerated and survival rates in patients on acoramidis approached age-matched survival rates of individuals without ATTR-CM.
4. CRT upgrade benefits patients with HFrEF and ICD
   An upgrade from an implantable cardioverter-defibrillator (ICD) to a cardiac resynchronisation therapy defibrillator (CRT-D) reduced the risk for cardiovascular and other adverse outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and right ventricular (RV) pacing. Based on these BUDAPEST CRT Upgrade results, the authors concluded that patients with HFrEF with a pacemaker or ICD and RV pacing should receive a CRT upgrade immediately.
5. Results of FRAIL-AF trial might surprise cardiologists
   According to the findings of the FRAIL-AF trial, switching frail patients with atrial fibrillation from a VKA to a NOAC should not be considered without a clear indication. In contrast to the hypothesis of the research team, switching to a NOAC resulted in a significantly higher risk for bleeding among these patients.
6. Expedited transfer to specialized centre does not improve cardiac arrest outcomes
   Patients with resuscitated out-of-hospital cardiac arrest without ST elevation did not benefit from immediate transfer to a specialised cardiac arrest centre compared with a transfer to the nearest emergency department in terms of survival or neurological outcomes. These were the main results of the ARREST trial.

Enjoy listening!
Copyright ©2023 Medicom Medical Publishers



Posted on 11 September 202327 June 2024